LncRNA RHPN1-AS1 Promotes Cell Proliferation, Migration and Invasion Through Targeting miR-7-5p and Activating PI3K/AKT/mTOR Pathway in Hepatocellular Carcinoma

Xue-zhen Song, BD1, Xiao-ning Ren, MD1, Xiao-jun Xu, MD1, Xiao-xuan Ruan, MD1, Yi-li Wang, BD1, and Ting-Ting Yao, BD1

Abstract
Hepatocellular carcinoma (HCC) is a severe disease with high mortality in the world. Emerging evidence has suggested that lncRNAs play an important role in cancer progression, including HCC. This study aimed to comprehensively investigate the effect of lncRNA RHPN1 antisense RNA 1 (RHPN1-AS1) on HCC and its underlying molecular mechanism. In this study, we evaluated the expressions of lncRNA RHPN1-AS1 and miR-7-5p by qRT-RCR in both HCC tissue and HCC cells. Our findings showed that lncRNA RHPN1-AS1 was upregulated in HCC tissue and HCC cells, while miR-7-5p was downregulated. LncRNA RHPN1-AS1 expression in HCC patients was closely related to vascular invasion, tumor-node-metastasis (TNM) stage and barcelona clinic liver cancer (BCLC) stage. Furthermore, we quantified cell clone-formation ability, proliferation, migration and invasion of HCCLM3 and MHCC97 H cells using several assays (colony formation assay, 5-Ethynyl-2′-deoxyuridine (EdU) assay and transwell assay, respectively). Functional experiments confirmed that silencing lncRNA RHPN1-AS1 inhibited cell proliferation, migration and invasion in HCCLM3 and MHCC97 H cells. After that, bioinformatics analysis, dual luciferase reporter gene assay, qRT-PCR and western blot were used to investigate the molecular mechanism of lncRNA RHPN1-AS1 on HCC. Mechanistically, the rescue experiments demonstrated that miR-7-5p inhibitor reversed the inhibition effect of silencing lncRNA RHPN1-AS1 on HCCLM3 cells proliferation, migration and invasion. Moreover, silencing lncRNA RHPN1-AS1 also inhibited the activation of PI3K/AKT/mTOR pathway. Taken together our findings demonstrated that lncRNA RHPN1-AS1 could facilitate cell proliferation, migration and invasion via targeting miR-7-5p and activating PI3K/AKT/mTOR pathway in HCC.

Keywords
hepatocellular carcinoma, lncRNA RHPN1-AS1, proliferation, metastasis, miR-7-5p, PI3K/AKT/mTOR pathway

Abbreviations
(RHPN1-AS1), lncRNA RHPN1 antisense RNA 1; (HCC), hepatocellular carcinoma; (TNM), tumor-node-metastasis; (BCLC), barcelona clinic liver cancer; (miRNAs), MicroRNAs; (siNC), UCA1 siRNA negative control; (inhibitor NC), miR-7-5p inhibitor negative control; (mimics NC), miR-7-5p mimics negative control; (EdU), 5-Ethynyl-2′-deoxyuridine; (RHPN1-AS1-WT), pmirGLO-WT-RHPN1-AS1-3′-UTR; (RHPN1-AS1-MUT), pmirGLO-MUT-RHPN1-AS1-3′-UTR; (ceRNA), competing endogenous RNA.

Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers and ranks as the second most common cause of cancer-associated death all over the world.1 Despite a variety of therapeutic approaches have been improving in recent years, the survival of HCC patients is still poor due to recurrence and...
metastasis. Thus, the identification of new therapeutic strategies and molecular targets for the treatment of HCC is critical.

Long noncoding RNA (lncRNAs) are a class of RNA transcripts which are longer than 200 nucleotides and exhibit no protein coding ability. An increasing body of literature suggests lncRNA may be closely related to the pathogenesis of multiple malignancies. In HCC, lncRNAs have been demonstrated to participate in cell proliferation, migration and invasion. For example, lncRNA-AWPPH has been reported to promote cell proliferation and migration in HCC. Shen et al. have indicated that lncRNA TATDN1 accelerates proliferation and cell cycle progression in HCC. There have been some studies demonstrating abnormal lncRNA RHPN1 antisense RNA 1 (RHPN1-AS1) expression in several types of cancers, including breast cancer, squamous cell carcinoma and non-small cell lung cancer. However, the function of lncRNA RHPN1-AS1 on HCC is unclear.

MicroRNAs (miRNAs) are noncoding endogenous short RNA molecules of 19 to 25 nucleotides of length which are capable of modulating gene expression at the post-transcriptional level. More and more studies have indicated that miRNAs are involved in many types of cancers, including HCC. Numerous miRNAs such as miR-21, miR-141, miR-769-5p and miR-7-5p have been reported to be abnormally expressed in HCC and play an important role in modulating the proliferation, migration and invasion of HCC cells. Several recent studies have suggested that lncRNAs, act as “molecular sponges” of miRNAs and can affect the target mRNA expression and ultimately interfere with the occurrence and development of diseases. However, the relationship between lncRNA RHPN1-AS1 and miR-7-5p remains uninvestigated in HCC.

In this study, we therefore explored the effect of lncRNA RHPN1-AS1 on cell proliferation, migration and invasion in HCC and investigated the potential underlying molecular mechanisms. Our results revealed that lncRNA RHPN1-AS1 could facilitate cell proliferation, migration and invasion via targeting miR-7-5p and activating PI3K/AKT/mTOR pathway in HCC. Findings of our study may provide a new theoretical foundation for exploring novel treatments for HCC.

Methods

Patients and Tissue Samples

Paired HCC and adjacent normal liver tissues were obtained from 126 HCC patients at our hospital during July 2015 to June 2018. All samples were pathologically confirmed and immediately frozen in liquid nitrogen after resection. None of the patients received chemotherapy and radiotherapy before surgery. The characteristics of HCC patients were presented in Table 1. The protocol of this research has been approved by the Ethics Committee of our hospital. All patients have signed written informed consent.

| Clinical parameters | Number of cases = 126 | RHPN1-AS1 |
|---------------------|-----------------------|-----------|
| Age                 |                       |           |
| <60                 | 51                    | 25        |
| ≥60                 | 75                    | 38        |
| Gender              |                       |           |
| Male                | 112                   | 58        |
| Female              | 14                    | 5         |
| HBsAg               |                       |           |
| Positive            | 103                   | 53        |
| Negative            | 23                    | 10        |
| AFP (μg/l)          |                       |           |
| <400                | 85                    | 41        |
| ≥400                | 41                    | 22        |
| Tumor size (maximal diameter) |          |           |
| <5cm                | 60                    | 31        |
| ≥5cm                | 66                    | 32        |
| Number of tumors    |                       |           |
| Solitary            | 102                   | 51        |
| Multiple            | 24                    | 14        |
| Encapsulation       |                       |           |
| Complete            | 85                    | 39        |
| No                  | 41                    | 24        |
| Vascular invasion   |                       |           |
| Yes                 | 102                   | 56        |
| No                  | 24                    | 7         |
| TNM stage           |                       |           |
| I-II                | 103                   | 47        |
| III                 | 23                    | 16        |
| BCLC stage          |                       |           |
| A                   | 88                    | 38        |
| B-C                 | 38                    | 25        |
| Histologic differentiation |               |           |
| I-II                | 88                    | 42        |
| III-IV              | 38                    | 21        |

*p < 0.05. HBeAg, hepatitis B e-antigen; AFP, a-fetoprotein; TNM, tumor-node metastasis; BCLC, barcelona clinic liver cancer

Cell Cultures

The immortalized normal liver epithelial cell line (THLE-3) and 4 human HCC cell lines (Hep-3B, Huh7, MHCC97 H and HCCLM3) were obtained from the American Type Culture Collection (ATCC, USA). All cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, USA) containing 10% fetal bovine serum (FBS, Gibco) at 37°C in an humidified incubator containing 5% CO2.

Cell Transfection

The RHPN1-AS1 siRNA, miR-7-5p inhibitor and their corresponding negative controls were purchased from GENECHEM Co., Ltd. (Shanghai, China). HCCLM3 and MHCC97 H cells
were seeded into a 24-well plates at a density of $1 \times 10^5$ cell/well, and respectively transfected with RHPN1-AS1 siRNA, miR-7-5p inhibitor, UCA1 siRNA negative control (siNC) or miR-7-5p inhibitor negative control (inhibitor NC) by using Lipofectamine® 3000 (Invitrogen, USA). Subsequently, the transfected HCCLM3 and MHCC97 H cells were randomly assigned to 7 groups: Mock group (no treatment), siNC group (transfected with siNC), siRHPN1-AS1 group (transfected with RHPN1-AS1 siRNA), siNC + inhibitor NC group (transfected with siNC and inhibitor NC), siRHPN1-AS1 + inhibitor NC group (transfected with RHPN1-AS1 siRNA and inhibitor NC), siNC + miR-7-5p inhibitor group (transfected with siNC and miR-7-5p inhibitor) and siRHPN1-AS1 + miR-7-5p inhibitor group (transfected with RHPN1-AS1 siRNA and miR-7-5p inhibitor).

**Colony Formation Assay**

The clonal abilities of HCCLM3 and MHCC97 H cells were measured by using a colony formation assay. In brief, HCCLM3 and MHCC97 H cells were seeded in six-well plates at a concentration of 500 cells per well and cultured for 14 d to form colonies. Subsequently, the colonies were fixed with formaldehyde (4%) and stained with crystal violet (2%) for 20 min. Finally, the stained colonies were imaged and counted.

**5-Ethynyl-2’-Deoxyuridine (EdU) Assay**

The proliferation abilities of HCCLM3 and MHCC97 H cells were determined by using an EdU kit (Roche, Germany) according to the manufacturer’s protocol. Simply, the transfected HCCLM3 and MHCC97 H cells were seeded into 6-well plate and then incubated with EdU solution. Subsequently, cell nuclei were stained with DAPI. Finally, the EdU staining was visualized on a microscope (Carl Zeiss, Oberkochen, Germany).

**Transwell Assay**

The migration and invasion abilities of HCCLM3 and MHCC97 H cells were detected by using a transwell chamber (Corning, USA) according to the manufacturer’s protocol. Simply, the transfected HCCLM3 and MHCC97 H cells were plated into the upper chamber at a density of $5 \times 10^4$ cells/well. For the invasion assay, the upper chamber was pre-coated with Matrigel (BD Biosciences, USA). The bottom chamber was filled with 500 μL DMEM containing 10% FBS. After incubation for 24 h at 37°C, the upper chamber cells were carefully removed. And the lower membrane cells were fixed in formaldehyde for 20 min, and then stained with crystal violet (Beyotime, China) for 30 min. Finally, images were collected using an optical microscope (Olympus, Tokyo, Japan).

**Dual Luciferase Reporter Gene Assay**

Starbase3.0 was used to predict the relationship between lncRNA RHPN1-AS1 and miRNA. For the luciferase assay, the fragments of lncRNA RHPN1-AS1 containing the miR-7-5p targeting sites were inserted into pGL3 vector (Promega, USA) for constructing wild pmirGLO-WT-RHPN1-AS1-3’-UTR (RHPN1-AS1-WT) and mutant pmirGLO-MUT-RHPN1-AS1-3’-UTR (RHPN1-AS1-MUT). Subsequently, reporter vectors with miR-7-5p mimics and miR-7-5p mimics negative control (mimics NC) were respectively co-transfected into HCCLM3 and MHCC97 H cells by Lipofectamine 3000 (Invitrogen, USA). At 48 h after transfection, the fluorescence intensity was measured using a dual luciferase kit (Promega, USA).

**Real-Time Fluorogenic PCR Assays**

Total RNA from HCC tissue, normal liver tissue, normal liver cells and HCC cells was extracted using TRIZOL (TaKaRa, Shanghai, China). The total RNA was reverse transcribed into cDNA using Revert Aid First Strand cDNA Synthesis Kit (Thermo, USA). Subsequently, qRT-PCR was performed using SYBR green qPCR Master Mix (Thermo Scientific, USA) according to the manufacturer’s protocol. Primers sequences were as follows: lncRNA RHPN1-AS1 F: 5’-GCTCTGTCATCAAGTCTCT-3’, R: 5’-GCACAGGACACAGAATGATCC-3’, GAPDH F: 5’-TCCCTGACTTACAACGCAC-3’, R: 5’-CACCCGTGTGCTAGCCAAATTC-3’, miR-7-5p F: 5’-TGGTGTGTTGAT-3’, R: 5’-TCCTCTGACTTACAACGCAC-3’; GAPDH: 5’-GCACAGGACACAGAATGATCC-3’, R: 5’-CACCCGTGTGCTAGCCAAATTC-3’, miR-7-5p F: 5’-TGGTGTGTTGAT-3’, R: 5’-TCCTCTGACTTACAACGCAC-3’, U6 F: 5’-CACCTTGAGGTCGCCAGGT-3’, R: 5’-ATCACCCGATCGATACGATGA-3’. GAPDH and U6 were respectively used as internal controls of lncRNA RHPN1-AS1 and miR-7-5p.

**Western Blot Analysis**

Total proteins from HCCLM3 and MHCC97 H cells were extracted using RIPA lysis buffer. Protein samples (50 μg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to a polyvinylidene difluoride membrane. The membranes were blocked with 5% non-fat milk for 2 h at room temperature. The membranes were then incubated with the primary antibodies against P.I3 K (#4249, 1:1000, Cell Signal, USA), p-P13 K (#3241, 1:500, Cell Signal), Akt (#9272, 1:1000, Cell Signal), p-Akt (#0016, 1:500, Cell Signal), mTOR (1:1000, Cell Signal), p-mTOR (#2927, 1:1000, Cell Signal), GAPDH (#5174, 1:1000, Cell Signal) at 4°C overnight. Subsequently, the membranes were washed with TBS-T, then incubated with secondary antibodies (1:5000, Santa Cruz, USA) and respectively incubated in TBS-T for 2 h at room temperature. The immunoreactive signals were visualized by an ECL system (Thermo, USA).

**Statistical Analysis**

All statistical analyses were performed using SPSS 22.0 Statistical Software (Chicago, IL). The data were presented as the mean ± SD. Statistical significance was tested using the
Student’s t-test or one-way ANOVA followed by the Tukey’s post hoc test. A level of P < 0.05 was considered to be statistically significant.

Results

The Expression of IncRNA RHPN1-AS1 Is Upregulated in HCC and Associated With Clinical Parameters

qRT-PCR of HCC tissue compared to normal liver tissue showed a significantly increased expression of IncRNA RHPN1-AS1 in HCC (P < 0.0001) (Figure 1A). Similarly, the expression of IncRNA RHPN1-AS1 in THLE-3 cells was markedly lower than that in Hep-3B (P = 0.0038), Huh7 (P = 0.0013), MHCC97 H (P = 0.0006) and HCCLM3 cells (P = 0.0004) (Figure 1B). These results suggested that IncRNA RHPN1-AS1 was highly expressed in HCC. Furthermore, the results of our further analysis (presented in Table 1) indicated that IncRNA RHPN1-AS1 expression was closely related to vascular invasion (P < 0.05), tumor-node-metastasis (TNM) stage (P < 0.05) and barcelona clinic liver cancer (BCLC) stage (P < 0.05) in HCC patients.

IncRNA RHPN1-AS1 Targets Negatively Regulating miR-7-5p Expression

More and more studies have confirmed that IncRNAs may be function as a molecular sponge or a competing endogenous RNA (ceRNA) via competitively binding to miRNAs in modulating the progression of cancers. To shed some light on the potential molecular mechanisms by which IncRNA RHPN1-AS1 exerted its role on HCC, StarBase online tool was used to predict the miRNAs that binds to IncRNA RHPN1-AS1. As Figure 3A showed, there was the binding site between IncRNA RHPN1-AS1 and miR-7-5p. Dual luciferase reporter gene assay showed that the fluorescence intensity in HCCLM3 and MHCC97 H cells was significantly reduced by miR-7-5p mimics in the RHPN1-AS1-WT group (P = 0.0041; P = 0.0046), but there was no significant difference in the RHPN1-AS1-MUT group (P = 0.1744; P = 0.1545) (Figure 3B). The results of qRT-PCR revealed that the expression of miR-7-5p was decreased in HCC tissue compared with normal liver tissue (P < 0.0001) (Figure 3C) and the expression of miR-7-5p was negatively correlated with the expression of IncRNA RHPN1-AS1 in HCC tissue (P < 0.0001) (Figure 3D). In addition, miR-7-5p expression was lower in Hep-3B (P = 0.0032), Huh7 (P = 0.0020), MHCC97 H (P = 0.0008) and HCCLM3 cells (P = 0.0001) than in THLE-3 cells, as shown
by qRT-PCR (Figure 3E). All the results demonstrated that lncRNA RHPN1-AS1 could target negatively regulating miR-7-5p expression.

**lncRNA RHPN1-AS1 Promotes Cell Proliferation, Migration and Invasion by Regulating miR-7-5p in HCCLM3 Cells**

To further confirm the interaction between lncRNA RHPN1-AS1 and miR-7-5p in HCC, siRHPN1-AS1, miR-7-5p inhibitor, siNC and inhibitor NC were co-transfected into HCCLM3 cells. As shown in Figure 4A, the expression of miR-7-5p was significantly increased in siRHPN1-AS1 + inhibitor NC group compared with siNC + inhibitor NC group (P = 0.0004).

Conversely, the expression of miR-7-5p was significantly decreased in siNC + miR-7-5p inhibitor group compared with siNC + inhibitor NC group (P = 0.0043). The expression of miR-7-5p in siRHPN1-AS1 + miR-7-5p inhibitor group was markedly lower than that in siRHPN1-AS1 + inhibitor NC group (P = 0.0002), while its expression was dramatically higher than that in siNC + miR-7-5p inhibitor group (P = 0.0097), suggesting that the transfection was successful. Colony formation assay (Figure 4B) showed that cell clone numbers of HCCLM3 cells were dramatically decreased in siRHPN1-AS1 + inhibitor NC group compared with siNC + inhibitor NC group (P = 0.0013). Meanwhile, cell clone numbers in siNC + miR-7-5p inhibitor group were significantly higher than that in siNC + inhibitor NC group (P = 0.0106). When compared with siRHPN1-AS1 + miR-7-5p inhibitor
group, cell clone numbers were decreased in siRHPN1-AS1 + inhibitor NC group (P = 0.0017), but were increased in siNC + miR-7-5p inhibitor group (P = 0.0177). In addition, the EdU assay (Figure 4C) and transwell assay (Figure 4D) revealed that the proliferation, migration and invasion abilities of HCCLM3 cells were significantly reduced in siRHPN1-AS1 + inhibitor NC group compared with siNC + inhibitor NC group (P = 0.0021; P = 0.0111; P = 0.0002), while they were elevated in siNC + miR-7-5p inhibitor group (P = 0.0004; P = 0.0083; P = 0.0161). Meanwhile, compared with siRHPN1-AS1 + miR-7-5p inhibitor group, the proliferation, migration and invasion abilities of HCCLM3 cells were decreased in siRHPN1-AS1 + inhibitor NC group (P = 0.0019; P = 0.0069; P = 0.0014), but increased in siNC + miR-7-5p inhibitor group (P = 0.0032; P = 0.0066; P = 0.0171). Therefore, our data revealed that lncRNA RHPN1-AS1 could promote cell proliferation, migration and invasion by regulating miR-7-5p in HCCLM3 cells.

**IncRNA RHPN1-AS1 Activates the PI3K/AKT/mTOR Pathway in HCCLM3 and MHCC97 H Cells**

As shown in Figure 5, silencing lncRNA RHPN1-AS1 significantly inhibited the phosphorylation of PI3 K, AKT and mTOR in HCCLM3 (P = 0.0001; P = 0.0019; P = 0.0013) and MHCC97 H cells (P = 0.0002; P = 0.0004; P = 0.0015). However, pretreatment with a PI3 K activator (740Y-P, 10 μM, MCE, USA) resulted in a significant increase in the phosphorylation of PI3 K, AKT and mTOR in HCCLM3 (P = 0.0003; P = 0.0002; P = 0.0011) and MHCC97 H cells (P = 0.0002; P = 0.0001; P = 0.0007). The results above suggested that lncRNA RHPN1-AS1 could activate PI3K/AKT/mTOR pathway in HCCLM3 and MHCC97 H cells.

**Discussion**

HCC is a global medical issue with a high incidence, especially in China. Although therapeutic approaches have been improving recently, the survival of HCC patients is still poor. It is therefore urgent to clarify the mechanisms of HCC progression and to explore innovative and effective treatment strategies for this disease. In this research, we demonstrated that lncRNA RHPN1-AS1 could activate PI3K/AKT/mTOR pathway in HCCLM3.

An increasing number of studies have suggested that lncRNAs play important roles in the progression of HCC. Previous reports have proved that the expression of IncRNA...
RHPN1-AS1 is upregulated in many malignancies, such as breast cancer,\textsuperscript{10} uveal melanoma\textsuperscript{21} and glioma.\textsuperscript{22} In our study, we demonstrated lncRNA RHPN1-AS1 was highly expressed in both HCC tissue and HCC cells, which was in line with previous findings. Furthermore, we also found that lncRNA RHPN1-AS1 expression was closely related to certain clinical parameters including vascular invasion, TNM stage and BCLC stage in HCC patients. Accumulating evidences have indicated that lncRNAs participate in a series of cellular processes, such as cell proliferation, migration, invasion and apoptosis.\textsuperscript{23,24}

![Figure 4](image)

**Figure 4.** Silencing lncRNA RHPN1-AS1 inhibited cell proliferation, migration and invasion by regulating miR-7-5p in HCCLM3 cells. (A) The expression of miR-7-5p was measured by qRT-PCR in HCCLM3 cells. (B) HCCLM3 cells clones number was detected by colony formation assay. (C) HCCLM3 cells proliferation ability was measured by EdU assay. (D) HCCLM3 cells migration and invasion abilities were detected by transwell assay. *P < 0.05, **P < 0.01, ***P < 0.001, vs. siNC + inhibitor NC group; #P < 0.05, ##P < 0.01, vs. siRHPN1-AS1 + inhibitor NC and siNC + miR-7-5p inhibitor group.
example, IncRNA FAM83H-AS1 is reported to facilitate cell proliferation, migration and invasion in HCC. Liu et al. have indicated that IncRNA MEG3 could inhibit cell proliferation and promote cell apoptosis in HCC. A study by Zhang et al. has confirmed that IncRNA XIST could promote cell proliferation and migration through targeting PDCD4 in HCC. In our present study, we investigated the effect of IncRNA RHPN1-AS1 on HCC cells and found that IncRNA RHPN1-AS1 could facilitate HCC cell proliferation, migration and invasion.

The molecular mechanism underlying the roles of IncRNAs is complex. One of the most common mechanisms of IncRNAs is to competitively bind miRNAs and regulate the effect of miRNAs on their targets. In recent years, IncRNA RHPN1-AS1 has been reported to act as a ceRNA of miRNAs and play a vital role in multiple tumors by antagonizing miRNAs functions and regulating the expression of miRNA targets. Cui et al. have reported that IncRNA RHPN1-AS1 could facilitate proliferation and invasion of glioma cells through targeting miR-625. This study focused on downstream miRNAs of IncRNA RHPN1-AS1, as a large number of miRNAs act as tumor suppressors and oncogenes in HCC. In this study, bioinformatics analysis and dual luciferase reporter gene assay confirmed that miR-7-5p was a target gene of IncRNA RHPN1-AS1. It is reported that miR-7-5p is a tumor suppressor miRNA capable of modulating the development of various cancers. Our results showed that miR-7-5p expression was downregulated in HCC, which was consistent with previous studies. Hu et al.
have suggested that miR-7-5p mimics could markedly suppress the growth, migration and colony formation of human hepatoma cells.18 Similarly, our data also confirmed that miR-7-5p inhibitor could reverse the inhibitory effect of silencing lncRNA RHPN1-AS1 on proliferation, migration and invasion of HCCLM3 cells, indicating that lncRNA RHPN1-AS1 could promote these activities by regulating miR-7-5p in HCC.

Previous studies have confirmed that PI3K/Akt/mTOR pathway is a key pathway in many human cancers,31 and it is reported to be the most widely studied pathway in HCC, active in 40-50% of HCC patients.32 In addition, the Akt pathway has been identified as a key mechanism of drug resistance in HCC.32 Currently, studies have reported that IncRNAs could regulate cell proliferation, migration, invasion and apoptosis through modulation of the PI3K/Akt/mTOR pathway in HCC.33,34 For example, downregulation of IncRNA NR027113 could suppress cell proliferation, migration and invasion by modulating the PI3K/Akt/mTOR pathway in HCC.35 Huang et al.36 have indicated that IncRNA CDKN2B-AS1 could promote cell proliferation and metastasis of human HCC by activating the PI3K/Akt/mTOR signaling pathway. Previous researches have confirmed that IncRNA PTTG3P could promote cell growth and metastasis through upregulating PTTG1 and activating the PI3K/Akt/mTOR pathway in HCC.37 In this study, we demonstrated that silencing lncRNA RHPN1-AS1 could inhibit the phosphorylation of PI3 K, Akt and mTOR. In addition, 740Y-P could reverse the inhibitory effect of silencing lncRNA RHPN1-AS1 on the phosphorylation of PI3 K, AKT and mTOR, suggesting that IncRNA RHPN1-AS1 could promote cell proliferation, migration and invasion by activating PI3K/AKT/mTOR pathway in HCC.

Conclusion

In conclusion, our work confirmed that IncRNA RHPN1-AS1 expression was upregulated in both HCC tissue and HCC cells. In addition, we further demonstrated that IncRNA RHPN1-AS1 could facilitate cell proliferation, migration and invasion via targeting miR-7-5p and activating PI3K/AKT/mTOR pathway in HCC. Our research provides a novel regulatory mechanism of IncRNA RHPN1-AS1 on HCC and may provide a reference for the future treatment of HCC.

Authors’ Note

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request. The protocol of this research has been approved by the Ethics Committee of Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University (certificate no. 20200029). All patients have signed written informed consent.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Xue-zhen Song https://orcid.org/0000-0002-6508-3615

References

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-386. doi: 10.1002/ijc.29210
2. Yang PC, Ho CM, Hu RH, Ho MC, Wu YM, Lee PH. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma. World J Hepatol. 2016;8(31):1309-1317. doi:10.4254/wjh.v8.i31.1309
3. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452-463. doi:10.1016/j.ccell.2016.03.010
4. Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018;109(7):2093-2100. doi:10.1111/cas.13642
5. Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med. 2018;24(3):257-277. doi:10.1016/j.molmed.2018.01.001
6. Parasramka MA, Maji S, Matsuda A, Yan IK, Patell T. Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma. Pharmacol Ther. 2016;161:67-78. doi:10.1016/j.pharmthera.2016.03.004
7. Smekalova EM, Kotelevtsev YV, Leboeuf D, et al. lncRNA in the liver: prospects for fundamental research and therapy by RNA interference. Biochimie. 2016;131:159-172. doi:10.1016/j.biochi.2016.06.007
8. Zhao X, Liu Y, Yu S. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker. Biochim Biophys Acta Mol Basis Dis. 2017;1863(7):1805-1816. doi:10.1016/j.bbadis.2017.04.014
9. Shen C, Xu Y, Lu TF, Zhang JJ, Qian YB, Xu N. LncRNA TATDN1 induces the progression of hepatocellular carcinoma via targeting miRNA-6089. Eur Rev Med Pharmacol Sci. 2019;23(15):6459-6466. doi:10.26355/eurrev_201908_18529
10. Zheng S, Lv P, Su J, Miao K, Xu H, Li M. Silencing of the long non-coding RNA RHPN1-AS1 suppresses the epithelial-to-mesenchymal transition and inhibits breast cancer progression. Am J Transl Res. 2019;11(6):3505-3517.
11. Qiu X, Lei Z, Wang Z, et al. Knockdown of LncRNA RHPN1-AS1 inhibits cell migration, invasion and proliferation in head and neck squamous cell carcinoma. J Cancer. 2019;10(17):4000-4008. doi:10.7150/jca.29029
12. Li X, Zhang X, Yang C, Cui S, Shen Q, Xu S. The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC. Cell Cycle. 2018;17(14):1772-1783. doi:10.1080/15384101.2018.1496745
13. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian micro-RNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835-840. doi:10.1038/nature09267
14. Li D, Zhang J, Li J. Role of miRNA sponges in hepatocellular carcinoma. Clin Chim Acta. 2020;500:10-19. doi:10.1016/j.cca.2019.09.013
15. Wang Y, Zhang P, Yuan M, Li X. Overexpression of miRNA-21 promotes the proliferation and invasion in hepatocellular carcinoma cells via suppressing SMAD7. Technol Cancer Res Treat. 2019;18:1533033819878686. doi:10.1177/1533033819878686
16. Zhao Y, Xu Z, Zhou J, Yang H. miR141 inhibits proliferation, migration and invasion in human hepatocellular carcinoma cells by directly downregulating TGFbetaR1. Oncol Rep. 2019. doi:10.3892/or.2019.7325
17. Xian Y, Wang L, Yao B, et al. MicroRNA-769-5p contributes to the proliferation, migration and invasion of hepatocellular carcinoma cells by attenuating RYBP. Biomed Pharmacother. 2019;118:109343. doi:10.1016/j.biopharm.2019.109343
18. Hu C, Zhu S, Wang J, et al. Schistosoma japonicum MiRNA-7-5p inhibits the growth and migration of hepatoma cells via cross-species regulation of S-phase kinase-associated protein 2. Front Oncol. 2019;9:175. doi:10.3389/fonc.2019.00175
19. Cesana M, Cavicchiarelli D, Legnini I, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011;147(2):358-369. doi:10.1016/j.cell.2011.09.028
20. DiStefano JK. Long noncoding RNAs in the initiation, progression, and metastasis of hepatocellular carcinoma. Noncoding RNA Res. 2017;2(3-4):129-136. doi:10.1016/j.ncrna.2017.11.001
21. Lu L, Yu X, Zhang L, et al. The long non-coding RNA RHPN1-AS1 promotes uveal melanoma progression. Int J Mol Sci. 2017;18(1):226. doi:10.3390/ijms18010226
22. Cui P, Su J, Li Q, Xu G, Zhu N. LncRNA RHPN1-AS1 targeting miR-625/REG3A promotes cell proliferation and invasion of glioma cells. OncoTargets Ther. 2019;12:7911-7921. doi:10.2147/ott.s209563
23. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629-641. doi:10.1016/j.cell.2009.02.006
24. Nagano T, Fraser P. No-nonsense functions for long noncoding RNAs. Cell. 2011;145(2):178-181. doi:10.1016/j.cell.2011.03.014
25. Ma YK, Shen TH, Yang XY. Upregulation of LncRNA FAM83H-AS1 in hepatocellular carcinoma promotes cell proliferation, migration and invasion by Wnt/beta-catenin pathway. Eur Rev Med Pharmacol Sci. 2019;23(18):7855-7862. doi:10.26355/eurrev_201909_18995
26. Liu Z, Chen JY, Zhong Y, Xie L, Li JS. LncRNA ME3G inhibits the growth of hepatocellular carcinoma cells by sponging miR-9-5p to upregulate SOX11. Braz J Med Biol Res. 2019;52(10):e8631. doi:10.1590/1414-431x20198631
27. Zhang Y, Zhu Z, Huang S, et al. LncRNA XIST regulates proliferation and migration of hepatocellular carcinoma cells by acting as miR-497-5p molecular sponge and targeting PDCD4. Cancer Cell Int. 2019;19(1):198. doi:10.1186/s12935-019-0909-8
28. Salmena L, Poliseno L, Tey Y, Kats L, Pandolfo P. A ceRNA hypothesis: the Rosetta stone of a hidden RNA language? Cell. 2011;146(3):353-358. doi:10.1016/j.cell.2011.07.014
29. Liu H, Huang J, Peng J, et al. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway. Mol Cancer. 2015;14.59. doi:10.1186/s12493-015-0298-0
30. Suto T, Yokobori T, Yajima R, et al. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis. 2015;36(3):338-345. doi:10.1093/carcin/bgu242
31. Zhang Z, Zhu J, Huang Y, Li W, Cheng H. MYO1B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway. Diagn Pathol. 2018;13(1):85. doi:10.1186/s13000-018-0763-3
32. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2008;68(16):6698-6707. doi:10.1158/0008-5472.can-08-0257
33. Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol. 2011;7(10):1149-1167. doi:10.2217/fon.11.95
34. Li W, Tan D, Zhang Z, Liang JJ, Brown RE. Activation of Akt/mTOR-p70S6 K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep. 2008;20(4):713-719.
35. Chen Z, Zhou ZY, He CC, Zhang JL, Wang J, Xiao ZY. Down-regulation of LncRNA NR027113 inhibits cell proliferation and metastasis via PTEN/PI3K/AKT signaling pathway in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2018;22(21):7222-7232. doi:10.26355/eurrev_201811_16256
36. Huang Y, Xiang B, Liu Y, Wang Y, Kan H. LncRNA CDKN2B-AS1 promotes cell proliferation and invasion in hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis. Mol Cancer. 2018;17(1):93. doi:10.1186/s12934-018-0841-x